Timothy Van Hauwermeiren

CIK: 0001816206

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (20.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

LXEO

Lexeo Therapeutics, Inc.

Director

DNLI

Denali Therapeutics Inc.

Director

ITOS

iTeos Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

LXEO
Lexeo Therapeutics, Inc.
Jun 25, 2026
Award(A)
Stock Option (right to buy)
Direct
35K shares-
DNLI
Denali Therapeutics Inc.
Jun 3, 2026
Award(A)
Direct
6.4K shares-
DNLI
Denali Therapeutics Inc.
Nov 4, 2025
Award(A)
Direct
10.6K shares-
LXEO
Lexeo Therapeutics, Inc.
Jun 26, 2025
Award(A)
Stock Option (right to buy)
Direct
22.9K shares-
ITOS
iTeos Therapeutics, Inc.
May 13, 2025
Exercise(M)
Direct
22.3K shares at avg. $4.30$96K

		Type	Shares	Price		Ownership
Jun 25, 2026	LXEO Lexeo Therapeutics, Inc.	Award(A) Stock Option (right to buy)	35,000	-	-	Direct
Jun 3, 2026	DNLI Denali Therapeutics Inc.	Award(A)	6,408	-	$0	Direct
Nov 4, 2025	DNLI Denali Therapeutics Inc.	Award(A)	10,632	-	-	Direct
Jun 26, 2025	LXEO Lexeo Therapeutics, Inc.	Award(A) Stock Option (right to buy)	22,916	-	-	Direct
May 13, 2025	ITOS iTeos Therapeutics, Inc.	Exercise(M)	22,346	$4.30	$96,088	Direct

1-5 of 5 transactions

About Van Hauwermeiren Timothy

Van Hauwermeiren Timothy (SEC CIK 0001816206) files insider reports with the SEC as Director of Lexeo Therapeutics, Inc. (LXEO), Director of Denali Therapeutics Inc. (DNLI) and Director of iTeos Therapeutics, Inc. (ITOS).

Signal8 holds 6 ownership filings by Van Hauwermeiren Timothy (1 Form 3, 5 Form 4), filed between May 14, 2025 and Jun 29, 2026. Those filings report 5 transactions, from May 13, 2025 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Van Hauwermeiren Timothy's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Van Hauwermeiren Timothy

Jun 25, 2026: Grant or award of LXEO derivative securities (Form 4, code A).
Jun 3, 2026: Grant or award of DNLI shares (Form 4, code A).
Nov 4, 2025: Grant or award of DNLI shares (Form 4, code A).
Jun 26, 2025: Grant or award of LXEO derivative securities (Form 4, code A).
May 13, 2025: Option exercise of ITOS shares (Form 4, code M).

Other insiders filing for Lexeo Therapeutics, Inc. (LXEO)

Tamayo Louis Edward, Chief Financial Officer
Bhalla Narinder Pal, Chief Medical Officer
Otero Jose Manuel, Chief Operating Officer
Townsend Richard Nolan, Chief Executive Officer
Altschuler Steven, Director
Agger Mette Kirstine, Director

How to read Form 4 transaction codes